1 / 10

Leveraging Government support and global partnerships to increase biologics manufacturing capacity

Leveraging Government support and global partnerships to increase biologics manufacturing capacity. What is BPA’s mission? fill key national capability gap in biologics development deliver key element to Smart State 10 year biotech strategy devise business model

tanith
Télécharger la présentation

Leveraging Government support and global partnerships to increase biologics manufacturing capacity

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Leveraging Government support and global partnerships to increase biologics manufacturing capacity

  2. What is BPA’s mission? • fill key national capability gap in biologics development • deliver key element to Smart State 10 year biotech strategy • devise business model • raise funds to support the model • identify commercial partner • design and build facility to commercial partner’s specs Leveraging Government support and global partnerships to increase biologics manufacturing capacity

  3. The capability gap Leveraging Government support and global partnerships to increase biologics manufacturing capacity

  4. Leveraging Government support and global partnerships to increase biologics manufacturing capacity • The Business Model • partner with Contract Manufacturing Organisation (CMO) • public funded capital infrastructure : industry attraction • design and build to CMO’s user requirement • landlord-tenant relationship • CMO has full autonomy in commercial operation • BPA has transitional support function for 2-3 years

  5. Leveraging Government support and global partnerships to increase biologics manufacturing capacity • Q - Why a CMO model? • A - a clear market trend over 5+ yrs • Time-to-market pressure • Offset risk – test the market first • Spare capital during clinical development • Allow developers to focus on areas of strength • IP generation • Clinical trials • Marketing and distribution

  6. Leveraging Government support and global partnerships to increase biologics manufacturing capacity • BPA’s partnering methodology • develop value proposition • leverage complementary clinical development providers • invite expressions of interest from CMO’S worldwide • request for proposals from selected group • evaluation of bids against set criteria • offer Terms Sheet to DSM Biologics

  7. Why DSM Biologics? • Track record • Financial stability • Commercial focus • No product IP – 100% customer service focus • Technology and commercial differentiators Strategic investment in biopharmaceutical manufacturing – a Queensland case study

  8. Leveraging Government support and global partnerships to increase biologics manufacturing capacity • Quick history • Dec 2009-BPA signs Terms Sheet with DSM Biologics • 2010 -concept design underway; negotiation of lease • 2010 -building shell underway • 2011 - completion of facilitydesign and tender package • Jan 2012 - internal fit out underway • Snapshot of the future • 2012 - complete fit out; procure process equipment • Jan 2013 - commissioning and qualification • Operations commence – July 2013

  9. Leverage other service providers: AIBN key linkage

More Related